Abata Therapeutics

Egle Therapeutics

This biotechnology company develops precision medicines that modulate regulatory T cells to treat patients with autoimmune diseases and cancer.

Quell Therapeutics

This clinical-stage company develops engineered T-regulatory cell therapies for patients with autoimmune diseases, inflammatory conditions and organ transplant rejection.

Regcell

This biotechnology company develops regulatory T-cell therapies using an epigenetic reprogramming platform to treat patients with autoimmune diseases and inflammatory conditions.

Dualyx

This company develops immune-modulating therapies targeting regulatory T cells to treat patients with autoimmune diseases.

Mozart Therapeutics

The company develops CD8 T regulatory cell modulators to treat patients with autoimmune and inflammatory diseases including type 1 diabetes.

Candid Therapeutics

This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.

Kyverna Therapeutics

This biopharmaceutical company develops chimeric antigen receptor T-cell therapies for patients with B-cell driven autoimmune diseases such as multiple sclerosis and lupus nephritis.

Autolus Therapeutics

This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.